Telo Genomics Corp. (FRA:3D0A)

Market Cap	2.80M -58.1%
Revenue (ttm)	n/a
Net Income	-1.66M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0015
Previous Close	0.0010
Day's Range	0.0015 - 0.0015
52-Week Range	0.0005 - 0.0795
Beta	n/a
RSI	44.63
Earnings Date	Feb 25, 2026

About Telo Genomics

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company’s TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SM...

• Industry: Electromedical and Electrotherapeutic Apparatus
• CEO: Sabine Mai
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3D0A

Financial Performance

Financial numbers in CAD